MicroRNA in Papillary Thyroid Carcinoma: A Systematic Review from 2018 to June 2020

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Oct 29

PMID 33113852

Citations 12

Authors

Liviu Hitu

Katalin Gabora

Eduard-Alexandru Bonci

Andra Piciu

Adriana-Cezara Hitu

Paul-Andrei Stefan

Doina Piciu

Affiliations

Soon will be listed here.

Abstract

The involvement of micro-ribonucleic acid (microRNAs) in metabolic pathways such as regulation, signal transduction, cell maintenance, and differentiation make them possible biomarkers and therapeutic targets. The purpose of this review is to summarize the information published in the last two and a half years about the involvement of microRNAs in papillary thyroid carcinoma (PTC). Another goal is to understand the perspective offered by the new findings. Main microRNA features such as origin, regulation, targeted genes, and metabolic pathways will be presented in this paper. We interrogated the PubMed database using several keywords: "microRNA" + "thyroid" + "papillary" + "carcinoma". After applying search filters and inclusion criteria, a selection of 137 articles published between January 2018-June 2020 was made. Data regarding microRNA, metabolic pathways, gene/protein, and study utility were selected and included in the table and later discussed regarding the matter at hand. We found that most microRNAs regularly expressed in the normal thyroid gland are downregulated in PTC, indicating an important tumor-suppressor action by those microRNAs. Moreover, we showed that one gene can be targeted by several microRNAs and have nominally described these interactions. We have revealed which microRNAs can target several genes at once.

Citing Articles

The diagnostic and prognostic role of miR-146b-5p in differentiated thyroid carcinomas.

Ferraz C, Cunha G, de Oliveira M, Tenorio L, Cury A, Padovani R Front Endocrinol (Lausanne). 2024; 15:1390743.

PMID: 39036050 PMC: 11257861. DOI: 10.3389/fendo.2024.1390743.

miR-331-5p Affects Motility of Thyroid Cancer Cell Lines and Regulates BID Expression.

Orlandella F, Imperlini E, Pane K, Luciano N, Braile M, De Stefano A Biomedicines. 2024; 12(3).

PMID: 38540271 PMC: 10968654. DOI: 10.3390/biomedicines12030658.

Upregulation and the clinical significance of KCNQ1OT1 and HAGLROS lncRNAs in papillary thyroid cancer: An observational study.

Mutlu Icduygu F, Akgun E, Ozgoz A, Hekimler Ozturk K, Sengul D, Alp E Medicine (Baltimore). 2023; 102(29):e34379.

PMID: 37478216 PMC: 10662889. DOI: 10.1097/MD.0000000000034379.

Nucleic Acids in Cancer Diagnosis and Therapy.

Kim T Cancers (Basel). 2023; 15(7).

PMID: 37046599 PMC: 10093127. DOI: 10.3390/cancers15071938.

Modulatory role of miRNAs in thyroid and breast cancer progression and insights into their therapeutic manipulation.

Ahmed R, Samanta S, Banerjee J, Kar S, Dash S Curr Res Pharmacol Drug Discov. 2022; 3:100131.

PMID: 36568259 PMC: 9780070. DOI: 10.1016/j.crphar.2022.100131.

References

Cao X, Bin H, Zang Z . MiR-128 suppresses the growth of thyroid carcinoma by negatively regulating SPHK1. Biomed Pharmacother. 2018; 109:1960-1966. DOI: 10.1016/j.biopha.2018.08.052. View

Shi D, Wang H, Ding M, Yang M, Li C, Yang W . MicroRNA-26a-5p inhibits proliferation, invasion and metastasis by repressing the expression of Wnt5a in papillary thyroid carcinoma. Onco Targets Ther. 2019; 12:6605-6616. PMC: 6701645. DOI: 10.2147/OTT.S205994. View

Sun W, Lan X, Zhang H, Wang Z, Dong W, He L . NEAT1_2 functions as a competing endogenous RNA to regulate ATAD2 expression by sponging microRNA-106b-5p in papillary thyroid cancer. Cell Death Dis. 2018; 9(3):380. PMC: 5841310. DOI: 10.1038/s41419-018-0418-z. View

Jiang K, Li G, Chen W, Song L, Wei T, Li Z . Plasma Exosomal miR-146b-5p and miR-222-3p are Potential Biomarkers for Lymph Node Metastasis in Papillary Thyroid Carcinomas. Onco Targets Ther. 2020; 13:1311-1319. PMC: 7025673. DOI: 10.2147/OTT.S231361. View

Liu Z, Wu Z, Li W, Wang L, Wan J, Zhong Y . MiR-96-5p promotes the proliferation, invasion and metastasis of papillary thyroid carcinoma through down-regulating CCDC67. Eur Rev Med Pharmacol Sci. 2019; 23(8):3421-3430. DOI: 10.26355/eurrev_201904_17706. View

Zang C, Sun J, Liu W, Chu C, Jiang L, Ge R . miRNA-21 promotes cell proliferation and invasion via VHL/PI3K/AKT in papillary thyroid carcinoma. Hum Cell. 2019; 32(4):428-436. DOI: 10.1007/s13577-019-00254-4. View

Xu C, Liu X, Li J, Zhao X, Xin D, Yu D . microRNA-539 functions as a tumor suppressor in papillary thyroid carcinoma via the transforming growth factor β1/Smads signaling pathway by targeting secretory leukocyte protease inhibitor. J Cell Biochem. 2019; 120(6):10830-10846. DOI: 10.1002/jcb.28374. View

Wang D, Tang X, Liang Q, Zeng X, Yang J, Xu J . microRNA-599 promotes apoptosis and represses proliferation and epithelial-mesenchymal transition of papillary thyroid carcinoma cells via downregulation of Hey2-depentent Notch signaling pathway. J Cell Physiol. 2019; 235(3):2492-2505. DOI: 10.1002/jcp.29154. View

Huang Y, Yu S, Cao S, Yin Y, Hong S, Guan H . MicroRNA-222 Promotes Invasion and Metastasis of Papillary Thyroid Cancer Through Targeting Protein Phosphatase 2 Regulatory Subunit B Alpha Expression. Thyroid. 2018; 28(9):1162-1173. DOI: 10.1089/thy.2017.0665. View

10.

Celano M, Rosignolo F, Maggisano V, Pecce V, Iannone M, Russo D . MicroRNAs as Biomarkers in Thyroid Carcinoma. Int J Genomics. 2017; 2017:6496570. PMC: 5606057. DOI: 10.1155/2017/6496570. View

11.

Sun W, Lan X, Wang Z, Dong W, He L, Zhang T . MicroRNA-144 inhibits proliferation by targeting WW domain-containing transcription regulator protein 1 in papillary thyroid cancer. Oncol Lett. 2018; 15(1):1007-1013. PMC: 5772735. DOI: 10.3892/ol.2017.7440. View

12.

Zarkesh M, Zadeh-Vakili A, Azizi F, Foroughi F, Akhavan M, Hedayati M . Altered Epigenetic Mechanisms in Thyroid Cancer Subtypes. Mol Diagn Ther. 2017; 22(1):41-56. DOI: 10.1007/s40291-017-0303-y. View

13.

Liu F, Lou K, Zhao X, Zhang J, Chen W, Qian Y . miR-214 regulates papillary thyroid carcinoma cell proliferation and metastasis by targeting PSMD10. Int J Mol Med. 2018; 42(6):3027-3036. PMC: 6202080. DOI: 10.3892/ijmm.2018.3902. View

14.

Fang T, Li J, Wu X . Shenmai injection improves the postoperative immune function of papillary thyroid carcinoma patients by inhibiting differentiation into Treg cells via miR-103/GPER1 axis. Drug Dev Res. 2018; 79(7):324-331. DOI: 10.1002/ddr.21459. View

15.

Wang R, Zhao L, Ji L, Bai L, Wen Q . Myocardial infarction associated transcript (MIAT) promotes papillary thyroid cancer progression via sponging miR-212. Biomed Pharmacother. 2019; 118:109298. DOI: 10.1016/j.biopha.2019.109298. View

16.

Sun Y, Liu Z, Yang B, Yu B . MicroRNA-486 inhibits cell proliferation, invasion and migration via down-regulating the TENM1 expressions and affecting ERK and Akt signaling pathways and epithelial-to-mesenchymal transition in papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci. 2019; 23(19):8429-8439. DOI: 10.26355/eurrev_201910_19155. View

17.

Yin J, Cheng X . MicroRNA-23a inhibits the growth of papillary thyroid carcinoma via regulating cyclin G1. Eur Rev Med Pharmacol Sci. 2019; 23(8):3431-3439. DOI: 10.26355/eurrev_201904_17707. View

18.

Wang Y, Wang B, Zhou H, Zhang X, Qian X, Cui J . MicroRNA-384 Inhibits the Progression of Papillary Thyroid Cancer by Targeting PRKACB. Biomed Res Int. 2020; 2020:4983420. PMC: 6973191. DOI: 10.1155/2020/4983420. View

19.

Pu Y, Xiang J, Zhang J . RETRACTED: KDM5B-mediated microRNA-448 up-regulation restrains papillary thyroid cancer cell progression and slows down tumor growth via TGIF1 repression. Life Sci. 2020; 250:117519. DOI: 10.1016/j.lfs.2020.117519. View

20.

Du Y, Zhu J, Chu B, Yang Y, Zhang S . MiR-548c-3p suppressed the progression of papillary thyroid carcinoma via inhibition of the HIF1α-mediated VEGF signaling pathway. Eur Rev Med Pharmacol Sci. 2019; 23(15):6570-6578. DOI: 10.26355/eurrev_201908_18543. View